Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer Clinical Trial

Official title:

The Efficacy and Safety of Anlotinib Combined With Nivolumab as a Second-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04211896
• Other study ID #: ANPD1-001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 1, 2020
• Est. completion date: January 1, 2022

Study information

• Verified date: December 2019
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: Renhua Guo, MD
• Phone: 025-68136360
• Email: rhguo[@]njmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the safety and efficacy of anlotinib in combination with nivilumab as second-line treatment in advanced NSCLC patients. The primary endpoint of the study is progression-free survival (PFS);the secondary endpoints are disease control rate (DCR), objective response rate (ORR), overall survival (OS) and safety.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: January 1, 2022
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female patients aged 18-75 years old;

2. ECOG PS:0-1,Expected Survival Time: Over 3 months;

3. Subjects with histologically or cytologically confirmed locally advanced and/or advanced NSCLC, with measurable nidus(using RECIST 1.1);

4. For local advanced or advanced NSCLC, disease progression occurred after first-line systemic treatment previously;

5. The negative patients in EGFR&ALK can participate or who positive in EGFR&ALK, have or have not drug tolerance after the treatment with relative targeted drugs;

6. main organs function is normal;

7. Signed and dated informed consent.

Exclusion Criteria:

1. have used Anlotinib before;

2. Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer);

3. examined as positive in EGFR&ALK mutation detection and never take the treatment of TKIs;

4. Previously (within 5 years) or presently suffering from other malignancies;

5. Symptomatic or uncontrolled brain metastases;

6. Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months or serious cardiac arrhythmia requiring medication;

7. Pregnancy or lactation.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• Anlotinib
Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
• Nivolumab
Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival (PFS)	PFS is defined as the time from the date of treatment to the first date of disease progression or death from any cause.	6 months
Secondary	Objective Response Rate (ORR)	Treatment response are defined as complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) according to Response Evaluation Criteria in Solid Tumor (RECISIT criteria, version 1.1). The percentage of patients who achieved CR and PR was defined as objective response rate (ORR)	each 42 days up to intolerance the toxicity or PD (up to 12 months)
Secondary	Disease control rate (DCR)	Treatment response are defined as complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) according to Response Evaluation Criteria in Solid Tumor (RECISIT criteria, version 1.1) and the percentage of patients who achieved CR, PR and SD was defined as disease control rate (DCR).	each 42 days up to intolerance the toxicity or PD (up to 12 months)
Secondary	Overall Survival (OS)	OS is calculated from diagnosis to death or last follow-up time.	12 months
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability		Until 30 day safety follow-up visit